Psilocybin, the active compound in hallucinogenic mushrooms, is edging into mainstream psychiatry in parts of Europe – with Switzerland already treating patients and the Czech Republic opening tightly supervised therapies. But France is holding back, limiting its use to clinical trials while doctors wait for stronger evidence of its efficacy.
Trump keeps carveout under CUSMA in new 10 per cent global tariff
...
Read moreDetails
